The Pharmaceutical / Biotechnology Group at Frost & Sullivan is pleased to announce its 2008 Quarterly Analyst Briefing Presentation on the targeted therapies segment of U.S. breast cancer therapeutics market to be held on Tuesday, February 26, 2008 at 12:00 p.m. CST / 1:00 p.m. EST.


Physicians treating breast cancer use varying combinations of cytotoxic, hormonal and targeted therapies. Future research into treatment strategies will focus on drugs with clear therapeutic potential, as well as minimal side effect profiles. Specialized therapies such as monoclonal antibodies, angiogenesis inhibitors, and vaccines could make a significant impact through targeted mechanisms of action and minimized toxicities. Combining these innovative highly specific therapies with existing cytotoxic and hormonal therapies is rapidly becoming the standard of care for treating breast cancer.


This briefing will benefit executives in the pharmaceutical and biotechnology industries, healthcare executives, and individuals interested in trends and information on breast cancer or the area of oncology.


Highlights of the briefing include: An analysis of patient populations and statistics, a look into current treatment trends and strategies and an analysis on pipelines and ongoing research into targeted therapeutics.


"The booming success of the targeted therapeutics segment and the extensive benefits of these new therapies, alongside new treatment strategies with more effective combinations of chemotherapy and hormonal drugs, are expected to drive the demand for drugs in this market. It is estimated that the targeted therapeutics segment alone could undergo the most significant growth over the forecast period reflecting the increasing importance of this segment to the overall market," notes Frost & Sullivan Research Analyst Misty Hughes.


To participate, please e-mail Melina Trevino at melina.trevinofrost with the following information: your full name, company name, title, telephone number, e-mail, address, city, state and country. Upon receipt of the above information, a registration link will be e-mailed to you.


Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

Frost & Sullivan

Bestsellers:


•   Buy Bactrim Without Prescription
•   Buy Savella Without Prescription
•   Buy Armour Without Prescription
•   Buy Flagyl Without Prescription